Taysha Gene Therapies (TSHA) Interest Coverage Ratio (2020 - 2026)
Taysha Gene Therapies (TSHA) reported Interest Coverage Ratio of 0.76 for Q1 2026, up 69.84% on a YoY basis from 0.45 in Q1 2025, and up 99.97% sequentially from 2358.33 in Q4 2025.
Taysha Gene Therapies (TSHA) Interest Coverage Ratio (2020 - 2026) Analysis & Trends
Taysha Gene Therapies (TSHA) has 7 years of Interest Coverage Ratio data on file, last reported at 0.76 in Q1 2026.
- For the quarter ending Q1 2026, Interest Coverage Ratio rose 69.84% year-over-year to 0.76; the trailing twelve-month figure through Mar 2026 stood at 2.32 (up 77.76% YoY), and the FY2025 full-year result was 1.35, down 68.82% from the prior year.
- Interest Coverage Ratio grew to 0.76 in Q1 2026, from 2358.33 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 5.14 in Q4 2024 to a low of 2358.33 in Q4 2025.
- A 5-year average of 148.56 and a median of 1.7 in 2024 frame the typical range for Interest Coverage Ratio.
- Across the five-year window, Interest Coverage Ratio soared 140.72% in 2024 and plunged 45984.09% in 2025, its largest moves.
- Tracing TSHA's Interest Coverage Ratio over 5 years: stood at 26.45 in 2022, then soared by 52.28% to 12.62 in 2023, then surged by 140.72% to 5.14 in 2024, then plunged by 45984.09% to 2358.33 in 2025, then soared by 99.97% to 0.76 in 2026.
- Business Quant data shows TSHA's Interest Coverage Ratio at 0.76 in Q1 2026, 2358.33 in Q4 2025, and 1.09 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Taysha Gene Therapies | 2.14 Bn | 2.14 Bn | - | -0.76 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.76 |
| Dec 31, 2025 | -2,358.33 |
| Sep 30, 2025 | -1.09 |
| Jun 30, 2025 | -1.02 |
| Mar 31, 2025 | -2.52 |
| Dec 31, 2024 | 5.14 |
| Sep 30, 2024 | -0.89 |
| Jun 30, 2024 | -2.22 |
| Mar 31, 2024 | -1.70 |
| Dec 31, 2023 | -12.62 |
| Sep 30, 2023 | -1.49 |
| Jun 30, 2023 | -0.73 |
| Mar 31, 2023 | -1.42 |
| Dec 31, 2022 | -26.45 |
| Sep 30, 2022 | -23.62 |
| Jun 30, 2022 | -44.92 |
| Mar 31, 2022 | -50.87 |
| Dec 31, 2021 | -1.95 |
| Sep 30, 2021 | -93.34 |
| Jun 30, 2021 | -9.06 |